DNAnexus, founded in 2009, is a cloud-based platform for biomedical informatics and data management. DNAnexus strives to provide security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health with the goal of accelerating medical discovery. The company is headquartered in Mountain View, California.

Register for Details

For more details on financing and valuation for DNAnexus, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about DNAnexus

To invest in DNAnexus pre-IPO

Can you invest in DNAnexus pre-IPO?

DNAnexus is a privately held company and is not publicly traded, therefore investing in DNAnexus pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of DNAnexus before it goes public?

You can seek to sell your shares in DNAnexus while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my DNAnexus shares?

To determine the value of your DNAnexus shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your DNAnexus shares. You can also learn more about how to sell your private shares before getting started.

Is DNAnexus a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about DNAnexus potential IPO

Will DNAnexus go IPO?

DNAnexus has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is DNAnexus’ IPO price?

The DNAnexus IPO price does not exist at this time, as DNAnexus is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to DNAnexus register for Forge Markets, today.

When was DNAnexus founded?

DNAnexus was founded in 2009.

What is DNAnexus funding to date?

DNAnexus has raised $1.14B to date.

Who are DNAnexus’s major investors?

Northpond Ventures
First Round Capital
Innovatus Capital Partners
First Round Capita
K9 Ventures
Felicis Ventures
Perceptive Advisors
Midcap Financial
Gv
Softtech Vc
Blackstone Growth
Tpg Capital
Wuxi Pharmatech
Regeneron Pharmaceuticals
Tpg Biotech
Existing Investors
Microsoft
Wuxi Nextcode
Claremont Creek Ventures
Foresite Capital

DNAnexus Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
03/08/2022 Series I $200MM $xx.xx $61.63B Blackstone Growth, Foresite Capital, Gv, Innovatus Capital Partners, Northpond Ventures, Perceptive Advisors
Price per Share
$xx.xx
Shares Outstanding
327,976,382
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Blackstone Growth, Foresite Capital, Gv, Innovatus Capital Partners, Northpond Ventures, Perceptive Advisors
06/09/2020 Series G $15.51MM $xx.xx $22.64B First Round Capital, Foresite Capital, Gv, Northpond Ventures, Perceptive Advisors, Regeneron Pharmaceuticals, Tpg Capital
Price per Share
$xx.xx
Shares Outstanding
42,529,695
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
First Round Capital, Foresite Capital, Gv, Northpond Ventures, Perceptive Advisors, Regeneron Pharmaceuticals, Tpg Capital
06/09/2020 Series H $47.15MM $xx.xx $22.64B First Round Capital, Foresite Capital, Gv, Northpond Ventures, Perceptive Advisors, Regeneron Pharmaceuticals, Tpg Capital
Price per Share
$xx.xx
Shares Outstanding
127,432,428
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
First Round Capital, Foresite Capital, Gv, Northpond Ventures, Perceptive Advisors, Regeneron Pharmaceuticals, Tpg Capital
02/06/2019 Series F-2 $14.43MM $xx.xx $13.59B Claremont Creek Ventures, Foresite Capital, Gv, Innovatus Capital Partners, Tpg Biotech, Wuxi Nextcode
Price per Share
$xx.xx
Shares Outstanding
40,909,900
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Claremont Creek Ventures, Foresite Capital, Gv, Innovatus Capital Partners, Tpg Biotech, Wuxi Nextcode
02/06/2019 Series F-1 $30.78MM $xx.xx $13.59B Claremont Creek Ventures, Foresite Capital, Gv, Innovatus Capital Partners, Tpg Biotech, Wuxi Nextcode
Price per Share
$xx.xx
Shares Outstanding
91,623,776
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Claremont Creek Ventures, Foresite Capital, Gv, Innovatus Capital Partners, Tpg Biotech, Wuxi Nextcode
01/02/2018 Series E $22.74MM $xx.xx $7.51B Claremont Creek Ventures, Existing Investors, Foresite Capital, Gv, Microsoft, Midcap Financial, Tpg Biotech, Wuxi Nextcode
Price per Share
$xx.xx
Shares Outstanding
67,694,865
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Claremont Creek Ventures, Existing Investors, Foresite Capital, Gv, Microsoft, Midcap Financial, Tpg Biotech, Wuxi Nextcode
04/22/2015 Series D $15MM $xx.xx $8.39B Wuxi Pharmatech
Price per Share
$xx.xx
Shares Outstanding
24,402,544
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Wuxi Pharmatech
01/03/2014 Series C $18.3MM $xx.xx $3.54B Claremont Creek Ventures, First Round Capita, Gv, Tpg Biotech
Price per Share
$xx.xx
Shares Outstanding
55,454,543
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Claremont Creek Ventures, First Round Capita, Gv, Tpg Biotech
10/12/2011 Series B $15.3MM $xx.xx $3.28B Felicis Ventures, First Round Capital, Gv, K9 Ventures, Softtech Vc, Tpg Biotech
Price per Share
$xx.xx
Shares Outstanding
7,559,292
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
4.1x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Felicis Ventures, First Round Capital, Gv, K9 Ventures, Softtech Vc, Tpg Biotech
08/03/2009 Series A $1.55MM $xx.xx $442.86MM First Round Capital
Price per Share
$xx.xx
Shares Outstanding
1,347,823
Liquidation Pref Order
7
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
2.8x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
First Round Capital
Updated on: Nov 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.